The global multiple sclerosis drugs market is expected to gain from the development of economical therapy to treat multiple sclerosis (MS), finds Fortune Business Insights in a report, titled “MULTIPLE SCLEROSIS DRUGS: GLOBAL MARKET ANALYSIS, INSIGHTS AND FORECAST, 2019-2026.” According to the report, the global market was worth US$ 23,460.3 Mn in 2018. The market is anticipated to expand at a CAGR of 6.7% and reach US$ 39,289.5 Mn by the end of 2026. The report offers a comprehensive overview of the multiple sclerosis drugs market.
As per the report, North America emerged dominant in the global market in 2018. The regional market was valued at US$ 13,826.7 Mn in 2018. The North America market is anticipated to expand and continue dominate the market during the forecast period 2019-2026. It is driven by the increasing demand for and high price of multiple sclerosis drugs. Additionally, several key market players operate in this region.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386
Leading Players operating in the Multiple Sclerosis Drugs Market are:
- Biogen
- Pfizer, Inc.
- F. Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Development of New Therapeutics to Propel Growth
In terms of route of administration, the injection segment was leading the market in 2018 and is anticipated to expand considerably over the forecast period. The growth witnessed is attributable to the active government recommendation for the injection.
Development of new therapeutics for treating multiple sclerosis and rising awareness about the disease are a expected to drive the global multiple sclerosis drugs market. Additionally, increasing per-capita income and increasing healthcare expenditure are some factors anticipated to fuel the demand in the global market.
Market Segmentation:
By Drug Class
- Immunomodulators
- Immunosuppressants
- Interferons
- Others
By Distribution Channels
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
By Geography
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Request a Sample Copy of the Multiple Sclerosis Drugs Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/multiple-sclerosis-drugs-market-100386
Detailed Table of Content:
- Introduction
- Research Scope
- Market Segmentation
- Research Methodology
- Definitions and Assumptions
- Executive Summary
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Market Trends
- Key Insights
- Prevalence of Multiple Sclerosis – For Key Countreis, 2018
- Regulatory Scenario – For Key Countries
- Patent Snapshot
- New Drug Class Launch
- Pipeline Analysis
- Key Industry Developments – Mergers, Acquisitions and Partnerships
- Global Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis, Insights and Forecast – By Drug Class
- Immunomodulators
- Immunosuppressants
- Interferons
- Others
- Market Analysis, Insights and Forecast – By Route of Administration
- Oral
- Injection
- Intramuscular
- Subcutaneous
- Intravenous
- Market Analysis, Insights and Forecast – By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
- Market Analysis, Insights and Forecast – By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- North America Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis – By Drug Class
- Immunomodulators
- Immunosuppressants
- Interferons
- Others
- Market Analysis – By Route of Administration
- Oral
- Injection
- Intramuscular
- Subcutaneous
- Intravenous
- Market Analysis – By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
- Market Analysis – By Country
- S.
- Canada
- Europe Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2015-2026
- Key Findings / Summary
- Market Analysis – By Drug Class
- Immunomodulators
- Immunosuppressants
- Interferons
- Others
- Market Analysis – By Route of Administration
- Oral
- Injection
- Intramuscular
- Subcutaneous
- Intravenous
- Market Analysis – By Distribution Channel
- Hospitals
- Retail Pharmacy
- Online Stores
- Market Analysis – By Countries/ Sub regions
- K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/multiple-sclerosis-drugs-market-100386
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
